Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Revenue (2016 - 2025)

Plus Therapeutics has reported Revenue over the past 13 years, most recently at $1.4 million for Q4 2025.

  • Quarterly Revenue fell 3.19% to $1.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.2 million through Dec 2025, down 10.49% year-over-year, with the annual reading at $5.2 million for FY2025, 10.49% down from the prior year.
  • Revenue was $1.4 million for Q4 2025 at Plus Therapeutics, down from $1.4 million in the prior quarter.
  • Over five years, Revenue peaked at $4.4 million in Q3 2023 and troughed at $73000.0 in Q3 2022.
  • The 4-year median for Revenue is $1.4 million (2025), against an average of $1.4 million.
  • Year-over-year, Revenue surged 5927.4% in 2023 and then crashed 66.91% in 2024.
  • A 4-year view of Revenue shows it stood at $127000.0 in 2022, then skyrocketed by 933.86% to $1.3 million in 2023, then rose by 7.54% to $1.4 million in 2024, then dropped by 3.19% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Revenue are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).